The global contract development and manufacturing organisation has more than doubled its sales in the US in the last two years
Sterling Pharma Solutions is the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry and specialises in handling hazardous chemistries. Its portfolio now includes more than 60 products with no single product representing more than 15% of its total sales.
Kevin Cook, CEO of Sterling Pharma Solutions said: “The US is a major market for Sterling due to the recent growth in the emerging pharma sector and significant presence of large pharma companies. As such, we have spent time investing in our presence and expanding our customer base in the country."
The increase in sales experienced by the company forms part of the Sterling Pharma Solutions’ growth strategy, which is focused on key markets including the US, UK, Japan and Europe. Sterling’s US sales now make up 68% of its business, having increased from £15.5m to £41m since 2016.
“We recently completed a successful general inspection audit with the FDA in February 2018 with no 483 observations. This is another significant milestone for the business and allows us to continue servicing our customers with the highest quality standards. We are committed to continuing to grow our presence in the US and maintaining our growth trajectory,” said Cook.
Sterling Pharma Solutions is currently exhibiting at CPhI North America in Philadelphia, 24-26 April 2018. Visit booth 1648 to find out more about the contract development and manufacturing organisation.